January 6, 2022
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Joint research agreement to establish a Social Collaboration Course,
Molecular Oncology, with the University of TokyoTOKYO, Japan, January 6, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,"SymBio") announced today that it has entered into a joint research agreement (the “Agreement”)
with the University of Tokyo to establish a Social Collaboration Course, Molecular Oncology, and toexplore the underlying molecular mechanisms of anti-tumor drug therapies using bendamustine andrigosertib, which are under development by SymBio as anticancer drugs.
Under the Agreement, SymBio will establish a Social Collaboration Course, Molecular Oncology(beginning on April 1, 2022) at the Graduate School of Pharmaceutical Sciences at the University ofTokyo, and conduct research in collaboration with Professor Shohei Hori, Graduate School ofPharmaceutical Sciences, and Professor Toshio Kitamura and Associate Professor Enomoto Yutaka,
Institute of Medical Sciences. Under the research collaboration, various tumor cells and evaluation
systems will be used, and epigenetic control and the cancer immune system will be explored toanalyze the pharmacological effects of bendamustine and rigosertib, alone or in combination withother drugs, toward the development of new indications for the compounds.
Professor Hori has achieved outstanding research work in elucidating the molecular mechanisms
involved in regulatory T cell function opening up a new research paradigm. Professor Kitamura madesignificant achievements in the research of hematopoietic tumors such as leukemia and thedifferentiation of hematopoietic stem cells and established an extensive network in his field. He iscurrently working to elucidate the molecular mechanisms during the development of hematopoietic
tumors caused by epigenetic abnormalities and developing novel therapies using hematopoietic tumor
models.
Statement of Fuminori Yoshida, President and Chief Executive Officer of SymBio: "This joint researchseeks to maximize business value through use of a more multifaceted approach from the molecularmechanism level to explore further potential benefits of bendamustine and rigosertib, either alone orin combination with each other or other drugs, in order to develop new therapeutic methods".
The Company does not expect the information presented herein to have any material impact on its
financial outlook for the fiscal year ending December 2021.

1

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug firstused in Germany in the 1970s, is now widely used in more than 50 countries with indications for lowgrade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
TREAKISYM® Intravenous Infusion, freeze-dried (FD) formulation, was approved in October 2010
for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell nonHodgkin's lymphoma and mantle cell lymphoma in Japan.

TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia inJapan in August 2016.

TREAKISYM® was approved for the additional indications of first-line treatment of low-grade Bcell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December 2016.

TREAKISYM® ready-to-dilute (RTD) liquid formulation was approved in Japan in September
2020 for all the above indications.

TREAKISYM® FD and RTD were approved for the additional indication of relapsed or refractory
DLBCL in March 2021 and April 2021, respectively.

About rigosertib
Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activationof RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K,
and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus
killing cancer cells. SymBio obtained the development and commercialization licensing rights forrigosertib from Onconova in July, 2011 for Japan and Korea.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma
USA, Inc. (Headquarters: Durham, North Carolina, President: Fuminori Yoshida). SymBio’s
underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading
global specialty biopharmaceutical company dedicated to address underserved medical needs.

2